摘要
目的对^(125)Ⅰ粒子植入治疗非小细胞肺癌进行剂量学验证。方法 37例确诊的非小细胞肺癌患者,由放射治疗计划系统(TPS)通过 CT 引导植入^(125)Ⅰ粒子,并行验证。定期进行复查。结果除2例无效外,10例患者的病灶消失,25例明显缩小;瘤体的平均吸收剂量为150.5 Cy,匹配周缘吸收剂量(D_(MP))为86.6 Cy,靶区90%体积的吸收剂量(D_(90))为92.4 Cy,D_(90)>D_(MP)。结论^(125)Ⅰ粒子植入治疗非小细胞肺癌安全可行。
Objective To validate the dosimetry of ^125I seed implantation in non-small cell lung eaneer（NSCLC）guided by CT. Methods ^125I seed was implanted in 37 eases confirmed NSCLC by the treatment planning system （TPS） and guided by CT image, then the radiation dose was validated and all cases were fellow up in certain duration. Results Except no response in 2 eases, tumors disappeared in 10 eases and markedly shrinked in 25 eases. The average irradiated absorbed dose by the tumor was 150.5 Gy, whereas the matched peripheral dose（DMP） was 86.6 Gy, and the irradiated absorbed dose of 90% target volume （ D90 ） was 92.4 Gy thus D90 〉 DMP Conclusion The therapy of ^125I seed implantation in NSCLC is safe and available.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2006年第1期21-23,共3页
Chinese Journal of Nuclear Medicine
